The study is being conducted to learn why some patients with Benign Prostatic Hyperplasia (BPH) do not respond to a commonly used treatment drug, Finasteride. The hope is to find ways to predict which patients will not respond to Finasteride so that, in the future, these patients can be identified prior to offering this treatment and they can be offered alternative treatment strategies in its place. The aim is to see if noninvasive techniques such as MRI can detect inflammation of the prostate to assist with early detection of those who will and who will not respond to Finasteride.
Male (physiological);
Age ≥ 50;
Eligible for treatment with 5ARI therapy;
Presence of lower urinary tract symptoms secondary to BPH;
Diagnosis of any prostatic malignancy or precancerous lesions (atypical glandular foci and prostatic intraepithelial neoplasia);
Treatment with 5ARI (Finasteride or Dutasteride) within six months of study enrollment;
Current urinary tract infection;
Previous pelvic radiation;
Beth Israel Deaconess Medical Center
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Collaborator